Hepatic fibrosis or cirrhosis screening trial
Part of Digestive system clinical trials.
This trial screens for liver scarring (fibrosis) or severe scarring (cirrhosis) caused by hepatitis B or C. It aims to find people who may benefit from further care or treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must sign a consent form agreeing to join
- You must be covered by French Social Security
- You must not be pregnant or breastfeeding
- You must not be under legal guardianship or unable to consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at tiny particles in the blood (extracellular vesicles) to see if they can help doctors understand and track liver disease. It includes healthy volunteers, people with diabetes and liver scarring, and people with cirrhosis, with the goal of finding better biomarkers.
This trial uses a blood test (FIB-4) to find liver scarring (fibrosis) in people who haven't been tested before. It aims to catch advanced liver disease early, which can help you get treatment sooner.
This trial looks for better ways to detect liver scarring (fibrosis) in people with long-term liver disease. It may help find problems earlier.
This study checks people who are at higher risk for liver scarring by using noninvasive tests. If those tests suggest significant scarring, the study may consider further testing, but not everyone will need a biopsy.
This study is for people with type 2 diabetes who may have early liver damage (fatty liver) but haven't yet developed severe scarring. It tests a simple screening program to find advanced liver fibrosis early, so it can be treated sooner.
This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.
Hear when a new Liver Pathology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.